Loading
PPM1D (Protein phosphatase 1D) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Ovarian cancer, Myeloproliferative neoplasms and 5 more.
Involved in the negative regulation of p53 expression. Required for the relief of p53-dependent checkpoint mediated cell cycle arrest. Binds to and dephosphorylates 'Ser-15' of TP53 and 'Ser-345' of CHEK1 which contributes to the functional inactivation of these proteins.
Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes genetic literature 0.38, affected pathway 0.34, literature 0.99, genetic association 0.72, somatic mutation 0.93, animal model 0.29). IntOGen calls it a driver in 6 cohorts (0 activating, 6 loss-of-function), covering Basal Cell Carcinoma, Invasive Breast Carcinoma, High-Grade Glioma, NOS, Lung Adenocarcinoma, Pilocytic Astrocytoma.
In plain words · PPM1D (Protein phosphatase 1D) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Ovarian cancer, Myeloproliferative neoplasms and 5 more.
PPM1D (Protein phosphatase 1D) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Ovarian cancer, Myeloproliferative neoplasms and 5 more.
Involved in the negative regulation of p53 expression. Required for the relief of p53-dependent checkpoint mediated cell cycle arrest.
No product in this corpus aims at PPM1D yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 1997. Earliest sequence paper UniProt cites for the protein: Fiscella et al, Proc. Natl. Acad. Sci. U.S.A, 1997, "Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner". Source.
Sources: HGNC HGNC:9277 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15297 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000170836 (association with cancer (MONDO_0004992) 0.81; per-cancer scores at or above 0.5: colorectal cancer 0.51, ovarian cancer 0.58, skin cancer 0.52, myeloproliferative neoplasm 0.56, breast cancer 0.71 (GraphQL API, CC0)); IntOGen PPM1D (driver in 6 cohorts (Act 0, LoF 6); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Involved in the negative regulation of p53 expression. Required for the relief of p53-dependent checkpoint mediated cell cycle arrest. Binds to and dephosphorylates 'Ser-15' of TP53 and 'Ser-345' of CHEK1 which contributes to the functional inactivation of these proteins. Mediates MAPK14 dephosphorylation and inactivation. Is also an important regulator of global heterochromatin silencing and critical in maintaining genome integrity. Location: Nucleus; Cytoplasm, cytosol (UniProt). Locus 17q23.3 (HGNC).
Query for this target: (TITLE:"PPM1D" OR ABSTRACT:"PPM1D" OR TITLE:"protein phosphatase, Mg2+/Mn2+ dependent 1D" OR ABSTRACT:"protein phosphatase, Mg2+/Mn2+ dependent 1D" OR TITLE:"Protein phosphatase 1D" OR ABSTRACT:"Protein phosphatase 1D" OR TITLE:"Wip1" OR ABSTRACT:"Wip1" OR TITLE:"PP2C-DELTA" OR ABSTRACT:"PP2C-DELTA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PPM1D, not a curated reading list.
Shares Paediatric low-grade glioma, Skin cancer (all types), IntOGen, Breast cancer (all types).
Shares Basal cell carcinoma, Skin cancer (all types), IntOGen, Ovarian cancer.
Shares Basal cell carcinoma, Skin cancer (all types), IntOGen, Breast cancer (all types).
Shares Basal cell carcinoma, Skin cancer (all types), IntOGen, Open Targets Platform.
Shares Basal cell carcinoma, Skin cancer (all types), IntOGen, Ovarian cancer.
Shares Clonal haematopoiesis (CHIP), Myeloproliferative neoplasms (PV, ET, myelofibrosis), IntOGen, Breast cancer (all types).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Skin cancer (all types), IntOGen, Ovarian cancer.
Shares Basal cell carcinoma, Skin cancer (all types), Open Targets Platform, Colorectal cancer.